Trial Profile
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Orally Administered BI 409306 During a 28-week Treatment Period as Adjunctive Therapy to Antipsychotic Treatment for the Prevention of Relapse in Patients With Schizophrenia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 May 2022
Price :
$35
*
At a glance
- Drugs Osoresnontrine (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim; Nippon Boehringer Ingelheim
- 09 Dec 2021 New source identified and integrated (Japan Pharmaceutical Information Center - Clinical Trials Information record: JapicCTI183893).
- 05 Oct 2021 Results of initial findings assessing nonadherence data from two Phase 2 clinical trials studying the efficacy and safety of BI 409306 in people with Schizophrenia (NCT03351244) or Attenuated Psychosis Syndrome (NCT03230097) presented at the 34th Annual Congress of the European College of Neuropsychopharmacology
- 30 Sep 2021 Status changed from completed to discontinued.